Validation of the technological process for the production of riamilovir-based solution for aerodispersible administration
- Authors: Prikhodko Y.S.1, Petrov A.Y.2, Knysh O.I.1, Kinev M.Y.2, Bolotova A.V.2, Artem’ev G.A.3, Okolelova M.S.4
-
Affiliations:
- Tyumen State Medical University
- Ural State Medical University
- Ural Federal University named after the first President of Russia B.N. Yeltsin
- Military Medical Academy
- Issue: Vol 43, No 3 (2024)
- Pages: 311-320
- Section: Original articles
- URL: https://journals.rcsi.science/RMMArep/article/view/275799
- DOI: https://doi.org/10.17816/rmmar633056
- ID: 275799
Cite item
Full Text
Abstract
BACKGROUND: An important step in the production of riamilovir-based solution for inhalation administration is the validation of critical stages of the technological process. First, a detailed study of all production steps, from the preparation of the initial ingredients to the final packaging, is carried out. Control tests are then conducted, including measuring key process parameters and analyzing the physical and chemical properties of the solution. One of the important aspects of process validation is also the training of production personnel. Proper understanding and adherence to all process instructions and requirements ensures that the process is followed correctly.
AIM: Carry out validation activities throughout the stages of the technological process for the production of a solution for inhalation administration based on the active substance “riamilovir”.
MATERIALS AND METHODS: The study was carried out using the developed Pilot Industrial Regulations for the production of the medicina. The quality assessment of pharmaceutical substances, excipients and pilot samples was carried out in accordance with the requirements of the State Pharmacopoeia of the Russian Federation and GMP rules.
RESULTS: It has been established that the technological scheme for the production of a solution based on the active substance “riamilovir” contains 6 main stages. The greatest risk is observed at the following stages: Auxiliary work 3. Obtaining water — risk of bacterial contamination. Тechnological process 4. Preparation and sterilizing filtration of the solution — risks of insufficient concentration and unsterility of the solution. Тechnological process 5. Dosing the solution into vials is a risk due to underfilling, as well as violation of sterility.
CONCLUSION: Validation of the technological process of production of solution for inhalation administration based on the active substance “riamilovir” has been carried out. Critical stages in the technological production process have been identified. The optimal parameters of the technological process have been determined and documented, leading to a predictable result — the release of a high-quality and safe drug.
Full Text
##article.viewOnOriginalSite##About the authors
Yuliya S. Prikhodko
Tyumen State Medical University
Author for correspondence.
Email: 2690-1998@mail.ru
ORCID iD: 0000-0002-5553-4814
SPIN-code: 5020-7287
Russian Federation, Tyumen
Alexander Yu. Petrov
Ural State Medical University
Email: uniitmp@yandex.ru
ORCID iD: 0000-0002-6199-9319
SPIN-code: 6297-2619
MD, Dr. Sci. (Pharmaceuticals), Professor
Russian Federation, YekaterinburgOl'ga I. Knysh
Tyumen State Medical University
Email: Knysh@tyumsmu.ru
ORCID iD: 0000-0001-6150-1683
SPIN-code: 4895-9550
MD, Dr. Sci. (Pharmaceuticals), Professor
Russian Federation, TyumenMikhail Yu. Kinev
Ural State Medical University
Email: 79630315545@yandex.ru
ORCID iD: 0000-0002-0241-558X
SPIN-code: 9441-8481
MD, Cand. Sci. (Pharmaceuticals)
Russian Federation, YekaterinburgAnna V. Bolotova
Ural State Medical University
Email: filimonovaann@yandex.ru
ORCID iD: 0000-0002-1654-9095
Russian Federation, Yekaterinburg
Grigоriy A. Artem’ev
Ural Federal University named after the first President of Russia B.N. Yeltsin
Email: 2690-1998@mail.ru
ORCID iD: 0000-0003-1306-4508
MD, Cand. Sci. (Technical)
Russian Federation, YekaterinburgMarina S. Okolelova
Military Medical Academy
Email: m.s.okolelova@gmail.com
ORCID iD: 0009-0001-4714-3434
SPIN-code: 4933-4507
MD, Cand. Sci. (Pharmaceuticals)
Russian Federation, Saint PetersburgReferences
- Bykov AА. About enterprise risk management. Issues of Risk Analysis. 2021;18(5):8–9. (In Russ.) EDN: SESFLM doi: 10.1057/9781137466297.0006
- Kinev MYu, Petrov AYu. Risk assessment in production technology nasal spray “Triazavirin spray” and validation of critical stages. Modern problems of science and education. 2015;(1–1):1852. EDN: VIFFSH. (In Russ.)
- Tatarnikova AA, Dvoryaninova OP, Kleimenova LN. Assessment of potential risks in the production of medicines. In: Student scientific forum2020. Materials of the International student scientific conference (2019–2020 Dec–Mar 01–06, Moscow). 2020;(2):74–75. Available from: https://publish2020.scienceforum.ru/ru/article/view?id=98 (In Russ.)
- Zavyalova IE, Sharakhova EF. Documentation support for validation of technological processes. Remedium. 2010;(2):51–52. EDN: KZGJAT. (In Russ.)
Supplementary files
